Luitpold News

Luitpold Pharmaceuticals receives Warning Letter from FDA

Luitpold Pharmaceuticals, Inc., is notifying the public that it received a Warning Letter from the New York District Office of the Food and Drug Administration (“FDA”) yesterday. The Warning Letter results from an inspection of Luitpold’s facilities held by FDA from February 9, 2011, through March 15, 2011.

In response to FDA’s concerns, Luitpold voluntarily suspended manufacturing operations from April 14, 2011 to May 16, 2011 during which time Luitpold focused its efforts on addressing the FDA observations, improving its processes and quality systems, and reviewing operations to ensure that it was capable of producing safe and effective drug products.
Click here to read the entire press release.

Luitpold Pharmaceuticals, Inc. Adequan (Polysulfated Glycosaminoglycan) Available

As of today, Luitpold Pharmaceuticals, Inc. Animal Health Division has an abundant supply of Adequan® i.m. (polysulfated glycosaminoglycan) 5ml single dose vials and 50mL multi-dose vials.
Read the full press release here.

Adequan is the Official Joint Therapy of USDF

The United States Dressage Federation (USDF) is extremely pleased to announce that Luitpold Pharmaceuticals, Inc. manufacturer of the joint therapy Adequan® (POLYSULFATED GLYCOSAMINOGLYCAN) renewed their commitment to sponsor the annual USDF National Convention and Symposium and the USDF year-end horse awards.
Read the press release here

Adequan was a proud sponsor of the 2010 AQHA World Show!

Forty-four states and 13 different countries were represented with over $2 million in awards and cash prizes given to top competitors at the 2010 AQHA World Championship show. Adequan is proud to sponsor and congratulates the contestants and winners of this year’s World Show.
Read the Story

For successful Arabian reining trainer joint health management pays off in show pen

Preventing lameness is the best policy when training performance horses that compete at a high level. Although that may not always be possible, Arabian horse reining trainer John O’Hara understands the impact of lameness. He manages his horses to maintain joint health throughout their performance careers.
Read the Story

Physical conditioning and daily care are essential for both horse and rider

Just finishing the course is a win, says Meg Sleeper, of her potential 100-mile ride in the 2010 Alltech FEI World Equestrian Games (WEG) on September 26. If the 42-year-old veterinary cardiologist from Frenchtown, New Jersey, is selected to be one of the five U.S. team riders on one of her two qualified horses, it will be the culmination of many years of training for both her and her horses.
Read the Story

Turnout, slow training and nutrition are keys to soundness

Maintaining joint health and the soundness of horses can be a challenge to owners, their farriers and their veterinarians. Whether a performance horse in training or a backyard horse for pleasure, most agree that soundness starts with good conformation and proper shoeing. But other management factors can help keep joints in healthy balance.
Read the Story

Adequan^®Joins Forces With Arabian Horse Association As The "Official Joint Therapy" Sponsor

The Arabian Horse Association announced that one of the nation's leaders in the fight against degenerative joint disease in horses, the veterinarian-trusted name of Adequan^® (polysulfated glycosaminoglycan) is now a corporate sponsor and the "Official Joint Therapy Sponsor of AHA."
Read the Press Release

Importance of a package insert

To assure the information you are reading is accurate and supported by research, read the package insert of the product. Any product with a package insert guarantees that you are using an effective, safe and well-documented treatment. These products are backed by the Food and Drug Administration (FDA) and have passed a stringent approval process.
Read the Story

Adequan^® I.M. now available in Multi-Dose vial

Luitpold Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved Adequan^® i.m. Multi-Dose (polysulfated glycosaminoglycan), a new convenient 10-Dose 50mL vial. After 20 years of proven performance, Adequan^® i.m. is the only FDA-approved treatment for non-infectious degenerative joint disease in horses. (Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption.)
Read the Press Release

Adequan^®becomes AQHA's Newest Corporate Partner

The New Year begins with a new partnership between Luitpold Pharmaceuticals’ Adequan^® and the American Quarter Horse Association. Luitpold is the manufacturer of the well-known joint therapy product Adequan^® (Polysulfated Glycosaminoglycan). Adequan^® is now the official equine joint therapy of AQHA.
Read the Press Release

When soundness counts, concentrate on conformation, correct shoeing and proven joint therapy

As anyone involved in the performance horse business knows, keeping horses sound and competitive is an ongoing challenge. Trainers, veterinarians and horse owners all agree that performance relies on the sound legs of the horse athlete.
Read the Story

2010 FTI Winter Equestrian Festival and Week Four Title Sponsor Adequan^® Work Together

The 2010 FTI Winter Equestrian Festival (WEF) is pleased to welcome their week four title sponsor, Adequan^®. Along with their week four title sponsorship, Adequan^® is the title sponsor of the $75,000 Adequan^® Grand Prix, CSI 2* on Sunday, February 7, and the overall circuit sponsor of the Young Jumper divisions for Five Year Olds, Six Year Olds, and Seven/Eight Year Olds. This is the sixth year that Adequan^® has sponsored at the FTI Winter Equestrian Festival.
Read the Press Release

• Archives
• 2009
• 2008
• 2007